Literature DB >> 12621030

Lipid binding inhibits alpha-synuclein fibril formation.

Min Zhu1, Anthony L Fink.   

Abstract

Parkinson's disease is the second most common neurodegenerative disorder, and the cause is unknown; however, substantial evidence implicates the aggregation of alpha-synuclein as a critical factor in the etiology of the disease. alpha-Synuclein is a relatively abundant brain protein of unknown function, and the purified protein is intrinsically unfolded. The amino acid sequence has seven repeats with an apolipoprotein lipid-binding motif, which are predicted to form amphiphilic helices. We have investigated the interaction of alpha-synuclein with lipid vesicles of different sizes and properties by monitoring the effects on the conformation of the protein and the kinetics of fibrillation. The nature of the interaction of alpha-synuclein with vesicles was highly dependent on the phospholipid composition, the ratio of alpha-synuclein to phospholipid, and the size of the vesicles. The strongest interactions were between alpha-synuclein and vesicles composed of 1,2-dipalmitoyl-sn-glycero-3-phosphate/1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-phospho-RAC-(1-glycerol)/1,2-dipalmitoyl-sn-glycero-3-phosphocholine and involved formation of helical structure in alpha-synuclein. A strong correlation was observed between the induction of alpha-helix in alpha-synuclein and the inhibition of fibril formation. Thus, helical, membrane-bound alpha-synuclein is unlikely to contribute to aggregation and fibrillation. Given that a significant fraction of alpha-synuclein is membrane-bound in dopaminergic neurons, this observation has significant physiological significance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621030     DOI: 10.1074/jbc.M210136200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  110 in total

1.  Effects of curvature and composition on α-synuclein binding to lipid vesicles.

Authors:  Elizabeth R Middleton; Elizabeth Rhoades
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling.

Authors:  Christine C Jao; Ani Der-Sarkissian; Jeannie Chen; Ralf Langen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-20       Impact factor: 11.205

3.  Lipid rafts mediate the synaptic localization of alpha-synuclein.

Authors:  Doris L Fortin; Matthew D Troyer; Ken Nakamura; Shin-ichiro Kubo; Malcolm D Anthony; Robert H Edwards
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

Review 4.  Folding and misfolding of alpha-synuclein on membranes.

Authors:  Igor Dikiy; David Eliezer
Journal:  Biochim Biophys Acta       Date:  2011-09-16

Review 5.  Dynamic structural flexibility of α-synuclein.

Authors:  Danielle E Mor; Scott E Ugras; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Neurobiol Dis       Date:  2015-12-31       Impact factor: 5.996

6.  Definition of a molecular pathway mediating α-synuclein neurotoxicity.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

7.  Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy.

Authors:  Susana Gonçalves; Tiago Fleming Outeiro
Journal:  Mol Neurobiol       Date:  2013-02-08       Impact factor: 5.590

8.  Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy.

Authors:  Elizabeth Rhoades; Trudy F Ramlall; Watt W Webb; David Eliezer
Journal:  Biophys J       Date:  2006-03-31       Impact factor: 4.033

Review 9.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

Review 10.  Interplay between α-synuclein amyloid formation and membrane structure.

Authors:  Emma I O'Leary; Jennifer C Lee
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2018-10-02       Impact factor: 3.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.